Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment

References

• Jensen RT, Battey JF, Spindel ER, et al. International union of pharmacology. LVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling and functions in normal and disease states. Pharmacol Rev. 2008;60:1–42.
   PubMed Web of Science ®Google Scholar
• Ramos-Alvarez I, Moreno P, Mantey SA, et al. Insights into bombesin receptors and ligands: highlighting recent advances. Peptides. 2015;72:128–144.
   PubMed Web of Science ®Google Scholar
• Gonzalez N, Moody TW, Igarashi H, et al. Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states. Curr Opin Endocrinol Diabetes Obes. 2008;15:58–64.
   PubMed Web of Science ®Google Scholar
• Majumdar ID, Weber HC. Biology of mammalian bombesin-like peptides and their receptors. Curr Opin Endocrinol Diabetes Obes. 2011;18:68–74.
   PubMed Web of Science ®Google Scholar
• Gonzalez N, Moreno P, Jensen RT. Bombesin receptor -subtype 3 as a potential target for obesity and diabetes. Exp Opin Ther Targets. 2015;19:1153–1170.
   PubMed Web of Science ®Google Scholar
• Uehara H, Gonzalez N, Sancho V, et al. Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs. Peptides. 2011;32:1685–1699.
   PubMed Web of Science ®Google Scholar
• Weber HC. Regulation and signaling of human bombesin receptors and their biological effects. Curr Opin Endocrinol Diabetes Obes. 2009;16:66–71.
   PubMed Web of Science ®Google Scholar
• Sayegh AI. The role of bombesin and bombesin-related peptides in the short-term control of food intake. Prog Mol Biol Transl Sci. 2013;114:343–370.
   PubMed Web of Science ®Google Scholar
• Weber HC. Gastrointestinal peptides and itch sensation. Curr Opin Endocrinol Diabetes Obes. 2015;22:29–33.
   PubMed Web of Science ®Google Scholar
• Cornelio DB, De Farias CB, Prusch DS, et al. Influence of GRPR and BDNF/TrkB signaling on the viability of breast and gynecologic cancer cells. Mol Clin Oncol. 2013;1:148–152.
   PubMedGoogle Scholar
• Petronilho F, Danielski LG, Roesler R, et al. Gastrin-releasing peptide as a molecular target for inflammatory diseases: an update. Inflamm Allergy Drug Targets. 2013;12:172–177.
   PubMedGoogle Scholar
• Yu Z, Ananias HJ, Carlucci G, et al. An update of radiolabeled bombesin analogs for gastrin-releasing peptide receptor targeting. Curr Pharm Des. 2013;19:3329–3341.
   PubMed Web of Science ®Google Scholar
• Varshney R, Hazari PP, Fernandez P, et al. (68)Ga-labeled bombesin analogs for receptor-mediated imaging. Recent Results Cancer Res. 2013;194:221–256.
   PubMedGoogle Scholar
• Wang LH, Coy DH, Taylor JE, et al. Desmethionine alkylamide bombesin analogs: a new class of bombesin receptor antagonists with potent antisecretory activity in pancreatic acini and antimitotic activity in Swiss 3T3 cells. Biochemistry (Mosc). 1990;29(3):616–622.
   Web of Science ®Google Scholar
• Wang LH, Coy DH, Taylor JE, et al. Des-Met carboxyl-terminally modified analogues of bombesin function as potent bombesin receptor antagonists, partial agonists, or agonists. J Biol Chem. 1990;265(26):15695–15703.
   PubMed Web of Science ®Google Scholar
• Sancho V, Di Florio A, Moody TW, et al. Bombesin receptor-mediated imaging and cytotoxicity: review and current status. Curr Drug Deliv. 2011;8:79–134.
   PubMed Web of Science ®Google Scholar
• Gonzalez N, Mantey SA, Pradhan TK, et al. Characterization of putative GRP- and NMB-receptor antagonist’s interaction with human receptors. Peptides. 2009;30:1473–1486.
   PubMed Web of Science ®Google Scholar
• Heinz-Erian P, Coy DH, Tamura M, et al. [D-Phe12]bombesin analogues: a new class of bombesin receptor antagonists. Am J Physiol. 1987;252:G439–G442.
   PubMed Web of Science ®Google Scholar
• Coy DH, Taylor JE, Jiang NY, et al. Short-chain pseudopeptide bombesin receptor antagonists with enhanced binding affinities for pancreatic acinar and Swiss 3T3 cells display strong antimitotic activity. J Biol Chem. 1989;264:14691–14697.
   PubMed Web of Science ®Google Scholar
• Von Schrenck T, Wang LH, Coy DH, et al. Potent bombesin receptor antagonists distinguish receptor subtypes. Am J Physiol. 1990;259:G468–G473.
   PubMed Web of Science ®Google Scholar
• Moreno P, Mantey SA, Nuche-Berenguer B, et al. Comparative pharmacology of bombesin receptor subtype-3, nonpeptide agonist MK-5046, a universal peptide agonist, and peptide antagonist Bantag-1 for human bombesin receptors. J Pharmacol Exp Ther. 2013;347:100–116.
   PubMed Web of Science ®Google Scholar
• Pradhan TK, Katsuno T, Taylor JE, et al. Identification of a unique ligand which has high affinity for all four bombesin receptor subtypes. Eur J Pharmacol. 1998;343:275–287.
   PubMed Web of Science ®Google Scholar
• Reubi JC, Wenger S, Schumuckli-Maurer J, et al. Bombesin receptor subtypes in human cancers: detection with the universal radoligand (125)I-[D-TYR(6), beta-ALA(11),PHE(13), NLE(14)] bombesin(6-14). Clin Cancer Res. 2002;8:1139–1146.
   PubMed Web of Science ®Google Scholar
• Moody TW, Moreno P, Jensen RT, Neuropeptides as lung cancer growth factors. Peptides. 2015;72:106–111.
   PubMed Web of Science ®Google Scholar
• Moody TW, Chan D, Fahrenkrug J, et al. Neuropeptides as autocrine growth factors in cancer cells. Curr Pharm Des. 2003;9:495–509.
   PubMed Web of Science ®Google Scholar
• Schulz S, Rocken C, Schulz S. Immunohistochemical detection of bombesin receptor subtypes GRP-R and BRS-3 in human tumors using novel antipeptide antibodies. Virchows Arch. 2006;449:421–427.
   PubMed Web of Science ®Google Scholar
• Jensen JA, Carroll RE, Benya RV. The case for gastrin-releasing peptide acting as a morphogen when it and its receptor are aberrantly expressed in cancer. Peptides. 2001;22:689–699.
   PubMed Web of Science ®Google Scholar
• Moody TW, Nuche-Berenguer B, Nakamura T, et al. EGFR transactivation by peptide G protein-coupled receptors in cancer. Curr Drug Targets. 2016;17(5):520–528.
   PubMed Web of Science ®Google Scholar
• Moody TW, Berna MJ, Mantey S, et al. Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells. Eur J Pharmacol. 2010;637:38–45.
   PubMed Web of Science ®Google Scholar
• Sotomayor S, Munoz-Moreno L, Carmena MJ, et al. Regulation of HER expression and transactivation in human prostate cancer cells by a targeted cytotoxic bombesin analog (AN-215) and a bombesin antagonist (RC-3095). Int J Cancer. 2010;127:1813–1822.
   PubMed Web of Science ®Google Scholar
• Thomas SM, Grandis JR, Wentzel AL, et al. Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells. Neoplasia. 2005;7:426–431.
   PubMed Web of Science ®Google Scholar
• Hohla F, Schally AV. Targeting gastrin releasing peptide receptors: new options for the therapy and diagnosis of cancer. Cell Cycle. 2010;9:1738–1741.
   PubMed Web of Science ®Google Scholar
• Cuttitta F, Carney DN, Mulshine J, et al. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer cells. Nature. 1985;316:823–826.
   PubMed Web of Science ®Google Scholar
• De Farias CB, Stertz L, Lima RC, et al. Reduced NGF secretion by HT-29 human colon cancer cells treated with a GRPR antagonist. Protein Pept Lett. 2009;16:650–652.
   PubMed Web of Science ®Google Scholar
• Jia Y, Shi H, Fan D. Significance of gastrin-releasing peptide in ovarian cancer ES2 cells. Oncol Lett. 2015;10:359–363.
   PubMed Web of Science ®Google Scholar
• Moody TW, Jensen RT, Garcia L, et al. Nonpeptide neuromedin B receptor antagonists inhibit the proliferation of C6 cells. Eur J Pharmacol. 2000;409:133–142.
   PubMed Web of Science ®Google Scholar
• Rick FG, Buchholz S, Schally AV, et al. Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers. Cell Cycle. 2012;11:2518–2525.
   PubMed Web of Science ®Google Scholar
• De Oliveira MS, Cechim G, Braganhol E, et al. Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models. J Neurooncol. 2009;93:191–201.
   PubMed Web of Science ®Google Scholar
• Rellinger EJ, Romain C, Choi S, et al. Silencing gastrin-releasing peptide receptor suppresses key regulators of aerobic glycolysis in neuroblastoma cells. Pediatr Blood Cancer. 2015;62:581–586.
   PubMed Web of Science ®Google Scholar
• Hong S-K, Yang S-Y, Yin S-H, et al. RC-3095, a gastrin-releasing peptide receptor antagonist, synergizes with gemcitabine to inhibit the growth of human pancreatic cancer CFPAC-1 in vitro and in vivo. Pancreas. 2014;43:15–21.
   PubMed Web of Science ®Google Scholar
• Xu Y, Jiang YF, Wu B. New agonist- and antagonist-based treatment approaches for advanced prostate cancer. J Int Med Res. 2012;40:1217–1226.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Bhola NE, Lui VW, et al. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol Cancer Ther. 2007;6:1414–1424.
   PubMed Web of Science ®Google Scholar
• Rick FG, Bi-Chaker A, Szalontay L, et al. Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist. Proc Natl Acad Sci U S A. 2013;110:2617–2622.
   PubMed Web of Science ®Google Scholar
• Moody TW, Nakagawa T, Kang Y, et al. Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation. J Mol Neurosci. 2006;28:231–238.
   PubMed Web of Science ®Google Scholar
• Marostica LL, De Barros AL, Silva JO, et al. Feasibility study with 99mTc-HYNIC-betaAla-Bombesin(7-14) as an agent to early visualization of lung tumour cells in nude mice. Nucl Med Commun. 2016;27:(4):372–376.
   Web of Science ®Google Scholar
• Langer DA, Kautzman D, Kane MA. Inhibition of proliferation of human small cell lung cancer cells expressing an autocrine system for gastrin releasing peptide by antisense oligodeoxynucleotides to gastrin releasing peptide receptor. Lung Cancer. 2002;36:235–242.
   PubMed Web of Science ®Google Scholar
• Fang J, Lu Y, Ouyang K, et al. Specific antibodies elicited by a novel DNA vaccine targeting gastrin-releasing peptide inhibit murine melanoma growth in vivo. Clin Vaccine Immunol. 2009;16:1033–1039.
   PubMed Web of Science ®Google Scholar
• Schwartsmann G, DiLeone LP, Horowitz M, et al. A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Invest New Drugs. 2006;24:403–412.
   PubMed Web of Science ®Google Scholar
• Kelley MJ, Linnoila RI, Avis IL, et al. Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest. 1997;112:256–261.
   PubMed Web of Science ®Google Scholar
• Kwekkeboom DJ, Krenning EP, Peptide receptor radionuclide therapy in the treatment of neuroendocrine tumors. Hematol Oncol Clin North Am. 2016;30:179–191.
   PubMed Web of Science ®Google Scholar
• Ruszniewski P 177Lu-DOTATATE significantly improves progession free survival in patients with mid-gut neuroendocrine tumors: results of the phase 111 NETTER-1 trial. European Cancer Conference, 2015, abstracts. Abstract LBA6, presented at the European Cancer Conference, 2015 (abstract)
   Google Scholar
• Sancho V, Moody TW, Mantey SA, et al. Pharmacology of putative selective hBRS-3 receptor agonists for human bombesin receptors (BnR): affinities, potencies and selectivity in multiple native and BnR transfected cells. Peptides. 2010;31:1569–1578.
   PubMed Web of Science ®Google Scholar
• Benya RV, Fathi Z, Battey JF, et al. Serines and threonines in the gastrin-releasing peptide receptor carboxyl terminus mediate internalization. J Biol Chem. 1993;268:20285–20290.
   PubMed Web of Science ®Google Scholar
• Benya RV, Kusui T, Battey JF, et al. Desensitizaton of neuromedin B receptors (NMB-R) on native and NMB-R transfected cells involves down-regulation and internalization. J Biol Chem. 1994;269:11721–11728.
   PubMed Web of Science ®Google Scholar
• Benya RV, Fathi Z, Pradhan T, et al. Gastrin-releasing peptide receptor-induced internalization, down-regulation, desensitization and growth: possible role of cAMP. Mol Pharmacol. 1994;46(2):235–245.
   PubMed Web of Science ®Google Scholar
• Mansi R, Abiraj K, Wang X, et al. Evaluation of three different families of bombesin receptor radioantagonists for targeted imaging and therapy of gastrin releasing peptide receptor (GRP-R) positive tumors. J Med Chem. 2015;58:682–691.
   PubMed Web of Science ®Google Scholar
• Cescato R, Maina T, Nock B, et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med. 2008;49:318–326.
   PubMed Web of Science ®Google Scholar
• Ginj M, Zhang H, Waser B, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A. 2006;103:16436–16441.
   PubMed Web of Science ®Google Scholar
• Abiraj K, Mansi R, Tamma M-L, et al. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. J Nucl Med. 2011;52:1970–1978.
   PubMed Web of Science ®Google Scholar
• Chatalic KL, Franssen GM, Van Weerden WM, et al. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer. J Nucl Med. 2014;55:2050–2056.
   PubMed Web of Science ®Google Scholar
• Gourni E, Mansi R, Jamous M, et al. N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imaging. J Nucl Med. 2014;55:1719–1725.
   PubMed Web of Science ®Google Scholar
• Maina T, Bergsma H, Kulkarni HR, et al. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [Ga]SB3 and PET/CT. Eur J Nucl Med Mol Imaging. 2015. (In press)
   PubMed Web of Science ®Google Scholar
• Stott Reynolds TJ, Schehr R, Liu D, et al. Characterization and evaluation of DOTA-conjugated Bombesin/RGD-antagonists for prostate cancer tumor imaging and therapy. Nucl Med Biol. 2015;42:99–108.
   PubMed Web of Science ®Google Scholar
• Varasteh Z, Aberg O, Velikyan I, et al. In vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging. PLoS ONE. 2013;8:e81932.
   Google Scholar
• Durkan K, Jiang Z, Rold TL, et al. A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] alphavbeta3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors. Nucl Med Biol. 2014;41:133–139.
   PubMed Web of Science ®Google Scholar
• Scopinaro F, Di Santo GP, Tofani A, et al. Fast cancer uptake of 99mTc-labelled bombesin (99mTc BN1). In Vivo. 2005;19:1071–1076.
   PubMed Web of Science ®Google Scholar
• Scopinaro F, De Vincentis G, Corazziari E, et al. Detection of colon cancer with 99mTc-labeled bombesin derivative (99mTc-leu13-BN1). Cancer Biother Radiopharm. 2004;19:245–252.
   PubMed Web of Science ®Google Scholar
• De Vincentis G, Scopinaro F, Varvarigou A, et al. Phase I trial of technetium [Leu13] bombesin as cancer seeking agent: possible scintigraphic guide for surgery? Tumori. 2002;88:S28–S30.
   Google Scholar
• Scopinaro F, Varvarigou AD, Ussof W, et al. Technetium labeled bombesin-like peptide: preliminary report on breast cancer uptake in patients. Cancer Biother Radiopharm. 2002;17:327–335.
   PubMed Web of Science ®Google Scholar
• Soluri A, Scopinaro F, De Vincentis G, et al. 99MTC [13LEU] bombesin and a new gamma camera, the imaging probe, are able to guide mammotome breast biopsy. Anticancer Res. 2003;23:2139–2142.
   PubMed Web of Science ®Google Scholar
• Scopinaro F, De Vincentis G, Varvarigou AD, et al. 99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes. Eur J Nucl Med Mol Imaging. 2003;30:1378–1382.
   PubMed Web of Science ®Google Scholar
• De Vincentis G, Remediani S, Varvarigou AD, et al. Role of 99mTc-bombesin scan in diagnosis and staging of prostate cancer. Cancer Biother Radiopharm. 2004;19:81–84.
   PubMed Web of Science ®Google Scholar
• Santos-Cuevas CL, Ferro-Flores G, Arteaga De Murphy C, et al. Targeted imaging of gastrin-releasing peptide receptors with 99mTc-EDDA/HYNIC-[Lys3]-bombesin: biokinetics and dosimetry in women. Nucl Med Commun. 2008;29:741–747.
   PubMed Web of Science ®Google Scholar
• Van de Wiele C, Dumont F, Vanden Broecke R, et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med. 2000;27:1694–1699.
   PubMedGoogle Scholar
• Van de Wiele C, Dumont F, Dierck RA, et al. Biodistribution and dosimetry of (99m)Tc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. J Nucl Med. 2001;42:1722–1727.
   PubMed Web of Science ®Google Scholar
• Van de Wiele C, Phonteyne P, Pauwels P, et al. Gastrin-releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry. J Nucl Med. 2008;49:260–264.
   PubMed Web of Science ®Google Scholar
• Chen Q, Ma Q, Chen M, et al. An exploratory study on 99mTc-RGD-BBN peptide scintimammography in the assessment of breast malignant lesions compared to 99mTc-3P4-RGD2. PLoS ONE. 2015;10:e0123401.
   Web of Science ®Google Scholar
• Ji T, Sun Y, Chen B, et al. The diagnostic role of 99mTc-dual receptor targeted probe and targeted peptide bombesin (RGD-BBN) SPET/CT in the detection of malignant and benign breast tumors and axillary lymph nodes compared to ultrasound. Hell J Nucl Med. 2015;18:108–113.
   PubMed Web of Science ®Google Scholar
• Mather SJ, Nock BA, Maina T, et al. GRP receptor imaging of prostate cancer using [(99m)Tc]Demobesin 4: a first-in-man study. Mol Imaging Biol. 2014;16:888–895.
   PubMed Web of Science ®Google Scholar
• Ananias HJ, Yu Z, Hoving HD, et al. Application of (99m)Technetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) SPECT/CT in prostate cancer patients: a first-in-man study. Nucl Med Biol. 2013;40:933–938.
   PubMed Web of Science ®Google Scholar
• Shariati F, Aryana K, Fattahi A, et al. Diagnostic value of 99mTc-bombesin scintigraphy for differentiation of malignant from benign breast lesions. Nucl Med Commun. 2014;35:620–625.
   PubMed Web of Science ®Google Scholar
• Dimitrakopoulou-Strauss A, Hohenberger P, Haberkorn U, et al. 68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDG. J Nucl Med. 2007;48:1245–1250.
   PubMed Web of Science ®Google Scholar
• Seiz M, Dimitrakopoulou-Strauss A, Schubert GA, et al. Differentiation between malignant transformation and tumour recurrence by (68)Ga-bombesin and (18)F-FDG-PET, in patients with low grade gliomas. Hell J Nucl Med. 2008;11:149–152.
   PubMed Web of Science ®Google Scholar
• Dimitrakopoulou-Strauss A, Seiz M, Tuettenberg J, et al. Pharmacokinetic studies of Ga-labeled Bombesin (Ga-BZH) and F-18 FDG PET in patients with recurrent gliomas and comparison to grading: preliminary results. Clin Nucl Med. 2011;36:101–108.
   PubMed Web of Science ®Google Scholar
• Strauss LG, Koczan D, Seiz M, et al. Correlation of the Ga-68-bombesin analog Ga-68-BZH3 with receptors expression in gliomas as measured by quantitative dynamic positron emission tomography (dPET) and gene arrays. Mol Imaging Biol. 2012;14:376–383.
   PubMed Web of Science ®Google Scholar
• Kahkonen E, Jambor I, Kemppainen J, et al. In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548. Clin Cancer Res. 2013;19:5434–5443.
   PubMed Web of Science ®Google Scholar
• Minamimoto R, Hancock S, Schneider B, et al. Pilot comparison of 68Ga-RM2 PET and 68Ga-PSMA PET in patients with biochemically recurrent prostate cancer. J Nucl Med. 2015. (in press).
   Google Scholar
• Zhang J, Li D, Lang L, et al. 68Ga-NOTA-Aca-BBN(7-14) PET/CT in healthy volunteers and glioma patients. J Nucl Med. 2016;57:9–14.
   PubMed Web of Science ®Google Scholar
• Wieser G, Mansi R, Grosu AL, et al. Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist–from mice to men. Theranostics. 2014;4:412–419.
   PubMed Web of Science ®Google Scholar
• Sah B-R, Burger IA, Schibli R, et al. Dosimetry and first clinical evaluation of the new 18F-radiolabeled bombesin analogue BAY 864367 in patients with prostate cancer. J Nucl Med. 2015;56:372–378.
   PubMed Web of Science ®Google Scholar
• Ma L, Yu P, Veerendra B, et al. In vitro and in vivo evaluation of Alexa Fluor 680-bombesin[7-14]NH2 peptide conjugate, a high-affinity fluorescent probe with high selectivity for the gastrin-releasing peptide receptor. Mol Imaging. 2007;6:171–180.
   PubMed Web of Science ®Google Scholar
• Cai Q-Y, Yu P, Besch-Williford C, et al. Near-infrared fluorescence imaging of gastrin releasing peptide receptor targeting in prostate cancer lymph node metastases. Prostate. 2013;73:842–854.
   PubMed Web of Science ®Google Scholar
• Chen H, Wan S, Zhu F, et al. A fast tumor-targeting near-infrared fluorescent probe based on bombesin analog for in vivo tumor imaging. Contrast Media Mol Imaging. 2014;9:122–134.
   PubMed Web of Science ®Google Scholar
• Heidari Z, Sariri R, Salouti M. Gold nanorods-bombesin conjugate as a potential targeted imaging agent for detection of breast cancer. J Photochem Photobiol B. 2014;130:40–46.
   PubMed Web of Science ®Google Scholar
• Jafari A, Salouti M, Shayesteh SF, et al. Synthesis and characterization of Bombesin-superparamagnetic iron oxide nanoparticles as a targeted contrast agent for imaging of breast cancer using MRI. Nanotechnology. 2015;26:075101.
   PubMed Web of Science ®Google Scholar
• Martin AL, Hickey JL, Ablack AL, et al. Synthesis of bombesin-functionalized iron oxide nanoparticles and their specific uptake in prostate cancer cells. J Nanopart Res. 2009;12:1599–1608.
   PubMed Web of Science ®Google Scholar
• Lee C-M, Jeong H-J, Cheong S-J, et al. Prostate cancer-targeted imaging using magnetofluorescent polymeric nanoparticles functionalized with bombesin. Pharm Res. 2010;27:712–721.
   PubMed Web of Science ®Google Scholar
• Bandari RP, Jiang Z, Reynolds TS, et al. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer. Nucl Med Biol. 2014;41:355–363.
   PubMed Web of Science ®Google Scholar
• Cui L, Liu Z, Jin X, et al. Evaluation of 188Re-MAG2-RGD-bombesin for potential prostate cancer therapy. Nucl Med Biol. 2013;40:182–189.
   PubMed Web of Science ®Google Scholar
• Jackson AB, Nanda PK, Rold TL, et al. 64Cu-NO2A-RGD-Glu-6-Ahx-BBN(7-14)NH2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer. Nucl Med Biol. 2012;39:377–387.
   PubMed Web of Science ®Google Scholar
• Jiang L, Miao Z, Liu H, et al. 177Lu-labeled RGD-BBN heterodimeric peptide for targeting prostate carcinoma. Nucl Med Commun. 2013;34:909–914.
   PubMed Web of Science ®Google Scholar
• Liu Z, Niu G, Wang F, et al. (68)Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imaging. 2009;36:1483–1494.
   PubMed Web of Science ®Google Scholar
• Liu Z, Li Z-B, Cao Q, et al. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer. J Nucl Med. 2009;50:1168–1177.
   PubMed Web of Science ®Google Scholar
• Aranda-Lara L, Ferro-Flores G, Ramirez FM, et al. Improved radiopharmaceutical based on 99mTc-Bombesin-folate for breast tumour imaging. Nucl Med Commun. 2016;37(4):377–386.
   PubMed Web of Science ®Google Scholar
• Marsouvanidis PJ, Melis M, De Blois E, et al. In vivo enzyme inhibition improves the targeting of [177Lu]DOTA-GRP(13-27) in GRPR-positive tumors in mice. Cancer Biother Radiopharm. 2014;29:359–367.
   PubMed Web of Science ®Google Scholar
• Reynolds TS, Bandari RP, Jiang Z, et al. Lutetium-177 labeled bombesin peptides for radionuclide therapy. Curr Radiopharm. 2016;9:33–43.
   PubMedGoogle Scholar
• Schroeder RP, Van Weerden WM, Bangma C, et al. Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues. Methods. 2009;48:200–204.
   PubMed Web of Science ®Google Scholar
• Mukai H, Wada Y, Watanabe Y. The synthesis of 64Cu-chelated porphyrin photosensitizers and their tumor-targeting peptide conjugates for the evaluation of target cell uptake and PET image-based pharmacokinetics of targeted photodynamic therapy agents. Ann Nucl Med. 2013;27:625–639.
   PubMed Web of Science ®Google Scholar
• Dubuc C, Langlois R, Benard F, et al. Targeting gastrin-releasing peptide receptors of prostate cancer cells for photodynamic therapy with a phthalocyanine-bombesin conjugate. Bioorg Med Chem Lett. 2008;18:2424–2427.
   PubMed Web of Science ®Google Scholar
• Sioud M, Mobergslien A. Efficient siRNA targeted delivery into cancer cells by gastrin-releasing peptides. Bioconjug Chem. 2012;23:1040–1049.
   PubMed Web of Science ®Google Scholar
• Safavy A, Raisch KP, Khazaeli MB, et al. Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes. J Med Chem. 1999;42:4919–4924.
   PubMed Web of Science ®Google Scholar
• Moody TW, Mantey SA, Pradhan TK, et al. Development of high affinity camptothecin-bombesin conjugates that have targeted cytotoxicity for bombesin receptor-containing tumor cells. J Biol Chem. 2004;279:23580–23589.
   PubMed Web of Science ®Google Scholar
• Moody TW, Sun L-C, Mantey SA, et al. In vitro and in vivo antitumor effects of cytotoxic camptothecin-bombesin conjugates are mediated by specific interaction with cellular bombesin receptors. J Pharmacol Exp Ther. 2006;318:1265–1272.
   PubMed Web of Science ®Google Scholar
• Wang C, Sun X, Wang K, et al. Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers. Drug Deliv. 2015. (in press).
   Google Scholar
• Moody TW, Pradhan T, Mantey SA, et al. Bombesin marine toxin conjugates inhibit the growth of lung cancer cells. Life Sci. 2008;82:855–861.
   PubMed Web of Science ®Google Scholar
• Liu S, Yang H, Wan L, et al. Enhancement of cytotoxicity of antimicrobial peptide magainin II in tumor cells by bombesin-targeted delivery. Acta Pharmacol Sin. 2011;32:79–88.
   PubMed Web of Science ®Google Scholar
• Sioud M, Mobergslien A. Selective killing of cancer cells by peptide-targeted delivery of an anti-microbial peptide. Biochem Pharmacol. 2012;84:1123–1132.
   PubMed Web of Science ®Google Scholar
• Yang H, Cai H, Wan L, et al. Bombesin analogue-mediated delivery preferentially enhances the cytotoxicity of a mitochondria-disrupting peptide in tumor cells. PLoS ONE. 2013;8:e57358.
   PubMed Web of Science ®Google Scholar
• vanderSpek JC, Sutherland JA, Zeng H, et al. Inhibition of protein synthesis in small cell lung cancer cells induced by the diphtheria toxin-related fusion protein DAB389 GRP. Cancer Res. 1997;57:290–294.
   PubMed Web of Science ®Google Scholar
• Zhou J, Chen J, Zhong R, et al. Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes. Clin Cancer Res. 2006;12:2224–2231.
   PubMed Web of Science ®Google Scholar
• De Barros AL, Mota L, Soares DC, et al. Tumor bombesin analog loaded long-circulating and pH-sensitive liposomes as tool for tumor identification. Bioorg Med Chem Lett. 2011;21:7373–7375.
   PubMed Web of Science ®Google Scholar
• Accardo A, Salsano G, Morisco A, et al. Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent. Int J Nanomedicine. 2012;7:2007–2017.
   PubMed Web of Science ®Google Scholar
• Accardo A, Aloj L, Aurilio M, et al. Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs. Int J Nanomedicine. 2014;9:1537–1557.
   PubMed Web of Science ®Google Scholar
• Accardo A, Mansi R, Salzano G, et al. Bombesin peptide antagonist for target-selective delivery of liposomal doxorubicin on cancer cells. J Drug Target. 2013;21:240–249.
   PubMed Web of Science ®Google Scholar
• De Barros AL, Mota L, Soares DC, et al. Long-circulating, pH-sensitive liposomes versus long-circulating, non-pH-sensitive liposomes as a delivery system for tumor identification. J Biomed Nanotechnol. 2013;9:1636–1643.
   PubMed Web of Science ®Google Scholar
• Accardo A, Mansi R, Morisco A, et al. Peptide modified nanocarriers for selective targeting of bombesin receptors. Mol Biosyst. 2010;6:878–887.
   PubMed Web of Science ®Google Scholar
• Chang Y-J, Yu C-Y, Hsu C-W, et al. Molecular imaging and therapeutic efficacy of 188Re-(DXR)-liposome-BBN in AR42J pancreatic tumor-bearing mice. Oncol Rep. 2012;28:1736–1742.
   PubMed Web of Science ®Google Scholar
• Kulhari H, Pooja D, Shrivastava S, et al. Peptide conjugated polymeric nanoparticles as a carrier for targeted delivery of docetaxel. Colloids Surf B Biointerfaces. 2014;117:166–173.
   PubMed Web of Science ®Google Scholar
• Hosta-Rigau L, Olmedo I, Arbiol J, et al. Multifunctionalized gold nanoparticles with peptides targeted to gastrin-releasing peptide receptor of a tumor cell line. Bioconjug Chem. 2010;21:1070–1078.
   PubMed Web of Science ®Google Scholar
• Chanda N, Kattumuri V, Shukla R, et al. Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity. Proc Natl Acad Sci U S A. 2010;107:8760–8765.
   PubMed Web of Science ®Google Scholar
• Jimenez-Mancilla N, Ferro-Flores G, Santos-Cuevas C, et al. Multifunctional targeted therapy system based on (99m) Tc/(177) Lu-labeled gold nanoparticles-Tat(49-57)-Lys(3) -bombesin internalized in nuclei of prostate cancer cells. J Labelled Comp Radiopharm. 2013;56:663–671.
   PubMed Web of Science ®Google Scholar
• Suresh D, Zambre A, Chanda N, et al. Bombesin peptide conjugated gold nanocages internalize via clathrin mediated endocytosis. Bioconjug Chem. 2014;25:1565–1579.
   PubMed Web of Science ®Google Scholar
• Qiao J, Hong T, Guo H, et al. Single-walled carbon nanotube-mediated small interfering RNA delivery for gastrin-releasing peptide receptor silencing in human neuroblastoma. Methods Mol Biol. 2013;1026:137–147.
   PubMedGoogle Scholar
• Qiao J, Hong T, Triana TS, et al. Magneto-fluorescent carbon nanotube-mediated siRNA for gastrin-releasing peptide receptor silencing in neuroblastoma. RSC Adv. 2013;3:4544–4551.
   PubMed Web of Science ®Google Scholar
• Dalm SU, Martens JW, Sieuwerts AM, et al. In vitro and in vivo application of radiolabeled gastrin-releasing peptide receptor ligands in breast cancer. J Nucl Med. 2015;56:752–757.
   PubMed Web of Science ®Google Scholar
• Gugger M, Reubi JC. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol. 1999;155:2067–2076.
   PubMed Web of Science ®Google Scholar
• Ni C, Zhao X, Sun T, et al. Role of gastrin-releasing peptides in breast cancer metastasis. Hum Pathol. 2012;43:2342–2347.
   PubMed Web of Science ®Google Scholar
• Chao C, Ives K, Hellmich HL, et al. Gastrin-releasing peptide receptor in breast cancer mediates cellular migration and interleukin-8 expression. J Surg Res. 2009;156:26–31.
   PubMed Web of Science ®Google Scholar
• Guojun W, Wei G, Kedong O, et al. A novel vaccine targeting gastrin-releasing peptide: efficient inhibition of breast cancer growth in vivo. Endocr Relat Cancer. 2008;15:149–159.
   PubMed Web of Science ®Google Scholar
• Bajo AM, Schally AV, Groot K, et al. Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers. Br J Cancer. 2004;90:245–252.
   PubMed Web of Science ®Google Scholar
• Schally AV. New approaches to the therapy of various tumors based on Peptide analogues. Horm Metab Res. 2008;40:315–322.
   PubMed Web of Science ®Google Scholar
• Ait-Mohand S, Fournier P, Dumulon-Perreault V, et al. Evaluation of 64Cu-labeled bifunctional chelate-bombesin conjugates. Bioconjug Chem. 2011;22:1729–1735.
   PubMed Web of Science ®Google Scholar
• Liu Z, Yan Y, Liu S, et al. (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer. Bioconjug Chem. 2009;20:1016–1025.
   PubMed Web of Science ®Google Scholar
• Parry JJ, Andrews R, Rogers BE. MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor. Breast Cancer Res Treat. 2007;18:110–117.
   Google Scholar
• Pujatti PB, Foster JM, Finucane C, et al. Evaluation and comparison of a new DOTA and DTPA-bombesin agonist in vitro and in vivo in low and high GRPR expressing prostate and breast tumor models. Appl Radiat Isot. 2015;96:91–101.
   PubMed Web of Science ®Google Scholar
• Retzloff LB, Heinzke L, Figureoa SD, et al. Evaluation of [99mTc-(CO)3-X-Y-Bombesin(7-14)NH2] conjugates for targeting gastrin-releasing peptide receptors overexpressed on breast carcinoma. Anticancer Res. 2010;30:19–30.
   PubMed Web of Science ®Google Scholar
• De Barros AL, Mota LD, Coelho MM, et al. Bombesin encapsulated in long-circulating pH-sensitive liposomes as a radiotracer for breast tumor identification. J Biomed Nanotechnol. 2015;11:342–350.
   PubMed Web of Science ®Google Scholar
• Heidari Z, Salouti M, Sariri R, Breast cancer photothermal therapy based on gold nanorods targeted by covalently-coupled bombesin peptide. Nanotechnology. 2015;26:195101.
   PubMed Web of Science ®Google Scholar
• Engel JB, Schally AV, Halmos G, et al. Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins. Endocr Relat Cancer. 2005;12:999–1009.
   PubMed Web of Science ®Google Scholar
• Mendoza-Sanchez AN, Ferro-Flores G, Ocampo-Garcia BE, et al. Lys3-bombesin conjugated to 99mTc-labelled gold nanoparticles for in vivo gastrin releasing peptide-receptor imaging. J Biomed Nanotechnol. 2010;6:375–384.
   PubMed Web of Science ®Google Scholar
• Scopinaro F, Varvarigou A, Ussof W, et al. Breast cancer takes up 99mTc bombesin. A Preliminary Report. Tumori. 2002;88:S25–S28.
   Google Scholar
• Van de Wiele C, Dumont F, Vanden Broecke R, et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med. 2000;27:1694–1699.
   PubMedGoogle Scholar
• Beer M, Montani M, Gerhardt J, et al. Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates. Prostate. 2012;72:318–325.
   PubMed Web of Science ®Google Scholar
• Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 1999;59:1152–1159.
   PubMed Web of Science ®Google Scholar
• Sun B, Halmos G, Schally AV, et al. Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. Prostate. 2000;42:295–303.
   PubMed Web of Science ®Google Scholar
• Ischia J, Patel O, Bolton D, et al. Expression and function of gastrin-releasing peptide (GRP) in normal and cancerous urological tissues. BJU Int. 2014;113 Suppl 2:40–47.
   PubMed Web of Science ®Google Scholar
• Korner M, Waser B, Rehmann R, et al. Early over-expression of GRP receptors in prostatic carcinogenesis. Prostate. 2014;74:217–224.
   PubMed Web of Science ®Google Scholar
• Schroeder RP, De Visser M, Van Weerden WM, et al. Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts. Int J Cancer. 2010;126:2826–2834.
   PubMed Web of Science ®Google Scholar
• Laukkanen MO, Castellone MD. Gastrin-releasing peptide receptor targeting in cancer treatment: emerging signaling networks and therapeutic applications. Curr Drug Targets. 2016;71(5):508–514.
   Web of Science ®Google Scholar
• Wen X, Chao C, Ives K, et al. Regulation of bombesin-stimulated cyclooxygenase-2 expression in prostate cancer cells. BMC Mol Biol. 2011;12:29.
   PubMed Web of Science ®Google Scholar
• Aprikian AG, Han K, Guy L, et al. Neuroendocrine differentiation and the bombesin/gastrin-releasing peptide family of neuropeptides in the progression of human prostate cancer. Prostate Suppl. 1998;8:52–61.
   PubMedGoogle Scholar
• Ananias HJ, Yu Z, Dierckx RA, et al. (99m)technetium-HYNIC(tricine/TPPTS)-Aca-bombesin(7-14) as a targeted imaging agent with microSPECT in a PC-3 prostate cancer xenograft model. Mol Pharm. 2011;8:1165–1173.
   PubMed Web of Science ®Google Scholar
• Bergmann R, Ruffani A, Graham B, et al. Synthesis and radiopharmacological evaluation of (6)(4)Cu-labeled bombesin analogs featuring a bis(2-pyridylmethyl)-1,4,7-triazacyclononane chelator. Eur J Med Chem. 2013;70:434–446.
   PubMed Web of Science ®Google Scholar
• Carlucci G, Ananias HJ, Yu Z, et al. Preclinical evaluation of a novel (1)(1)(1)In-labeled bombesin homodimer for improved imaging of GRPR-positive prostate cancer. Mol Pharm. 2013;10:1716–1724.
   PubMed Web of Science ®Google Scholar
• Carlucci G, Kuipers A, Ananias HJ, et al. GRPR-selective PET imaging of prostate cancer using [(18)F]-lanthionine-bombesin analogs. Peptides. 2015;67:45–54.
   PubMed Web of Science ®Google Scholar
• Craft JM, De Silva RA, Lears KA, et al. In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer. Nucl Med Biol. 2012;39:609–616.
   PubMed Web of Science ®Google Scholar
• Varasteh Z, Velikyan I, Lindeberg G, et al. Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging. Bioconjug Chem. 2013;24:1144–1153.
   PubMed Web of Science ®Google Scholar
• Dijkgraaf I, Franssen GM, McBride WJ, et al. PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog. J Nucl Med. 2012;53:947–952.
   PubMed Web of Science ®Google Scholar
• Ho C-L, Chen L-C, Lee W-C, et al. Receptor-binding, biodistribution, dosimetry, and micro-SPECT/CT imaging of 111In-[DTPA(1), Lys(3), Tyr(4)]-bombesin analog in human prostate tumor-bearing mice. Cancer Biother Radiopharm. 2009;24:435–443.
   PubMed Web of Science ®Google Scholar
• Lane SR, Nanda P, Rold TL, et al. Optimization, biological evaluation and microPET imaging of copper-64-labeled bombesin agonists, [64Cu-NO2A-(X)-BBN(7-14)NH2], in a prostate tumor xenografted mouse model. Nucl Med Biol. 2010;37:751–761.
   PubMed Web of Science ®Google Scholar
• Mu L, Honer M, Becaud J, et al. In vitro and in vivo characterization of novel 18F-labeled bombesin analogues for targeting GRPR-positive tumors. Bioconjug Chem. 2010;21:1864–1871.
   PubMed Web of Science ®Google Scholar
• Schroeder RP, Van Weerden WM, Krenning EP, et al. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts. Eur J Nucl Med Mol Imaging. 2011;38:1257–1266.
   PubMed Web of Science ®Google Scholar
• Schwarzenbock SM, Schmeja P, Kurth J, et al. Comparison of [C]Choline ([C]CHO) and [F]Bombesin (BAY 86-4367) as imaging probes for prostate cancer in a PC-3 prostate cancer xenograft model. Mol Imaging Biol. 2015. (in press).
   PubMed Web of Science ®Google Scholar
• Dumont RA, Tamma M, Braun F, et al. Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin. J Nucl Med. 2013;54:762–769.
   PubMed Web of Science ®Google Scholar
• Gourni E, Del PL, Kheirallah E, et al. Copper-64 labeled macrobicyclic sarcophagine coupled to a grp receptor antagonist shows great promise for PET imaging of prostate cancer. Mol Pharm. 2015;12:2781–2790.
   PubMed Web of Science ®Google Scholar
• Honer M, Mu L, Stellfeld T, et al. 18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors. J Nucl Med. 2011;52:270–278.
   PubMed Web of Science ®Google Scholar
• Lim JC, Cho EH, Kim JJ, et al. Biological evaluation of (177)Lu-labeled DOTA-Ala(SO3H)-Aminooctanoyl-Gln-Trp-Ala-Val-N methyl Gly-His-Statine-Leu-NH2 for gastrin-releasing peptide receptor-positive prostate tumor targeting. Nucl Med Biol. 2015;42:131–136.
   PubMed Web of Science ®Google Scholar
• Nanda PK, Pandey U, Bottenus BN, et al. Bombesin analogues for gastrin-releasing peptide receptor imaging. Nucl Med Biol. 2012;39:461–471.
   PubMed Web of Science ®Google Scholar
• Pan D, Xu YP, Yang RH, et al. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging. Amino Acids. 2014;46:1481–1489.
   PubMed Web of Science ®Google Scholar
• Pourghiasian M, Liu Z, Pan J, et al. (18)F-AmBF3-MJ9: A novel radiofluorinated bombesin derivative for prostate cancer imaging. Bioorg Med Chem. 2015;23:1500–1506.
   PubMed Web of Science ®Google Scholar
• Schroeder RP, Muller C, Reneman S, et al. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues. Eur J Nucl Med Mol Imaging. 2010;37:1386–1396.
   PubMed Web of Science ®Google Scholar
• Nanda PK, Wienhoff BE, Rold TL, et al. Positron-emission tomography (PET) imaging agents for diagnosis of human prostate cancer: agonist vs. antagonist ligands. In Vivo. 2012;26:583–592.
   PubMed Web of Science ®Google Scholar
• Levi J, Sathirachinda A, Gambhir SS. A high-affinity, high-stability photoacoustic agent for imaging gastrin-releasing peptide receptor in prostate cancer. Clin Cancer Res. 2014;20:3721–3729.
   PubMed Web of Science ®Google Scholar
• Sturzu A, Sheikh S, Echner H, et al. Rhodamine-marked bombesin: a novel means for prostate cancer fluorescence imaging. Invest New Drugs. 2014;32:37–46.
   PubMed Web of Science ®Google Scholar
• Prasanphanich AF, Retzloff L, Lane SR, et al. In vitro and in vivo analysis of [(64)Cu-NO2A-8-Aoc-BBN(7-14)NH(2)]: a site-directed radiopharmaceutical for positron-emission tomography imaging of T-47D human breast cancer tumors. Nucl Med Biol. 2009;36:171–181.
   PubMed Web of Science ®Google Scholar
• Yu Z, Carlucci G, Ananias HJ, et al. Evaluation of a technetium-99m labeled bombesin homodimer for GRPR imaging in prostate cancer. Amino Acids. 2013;44:543–553.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Wagh NK, Ogbomo SM, et al. Synthesis and in vitro and in vivo evaluation of hypoxia-enhanced 111In-bombesin conjugates for prostate cancer imaging. J Nucl Med. 2013;54:1605–1612.
   PubMed Web of Science ®Google Scholar
• Rybalov M, Ananias HJ, Hoving HD, et al. PSMA, EpCAM, VEGF and GRPR as imaging targets in locally recurrent prostate cancer after radiotherapy. Int J Mol Sci. 2014;15:6046–6061.
   PubMed Web of Science ®Google Scholar
• Mattei J, Achcar RD, Cano CH, et al. Gastrin-releasing peptide receptor expression in lung cancer. Arch Pathol Lab Med. 2014;138:98–104.
   PubMed Web of Science ®Google Scholar
• Liu Z, Huang J, Dong C, et al. 99mTc-labeled RGD-BBN peptide for small-animal SPECT/CT of lung carcinoma. Mol Pharm. 2012;9:1409–1417.
   PubMed Web of Science ®Google Scholar
• Du J, Li L. Which one performs better for targeted lung cancer combination therapy: pre- or post-bombesin-decorated nanostructured lipid carriers?. Drug Delivery. 2015. (in press).
   Google Scholar
• Yang H-J, Gu Y, Chen C, et al. Diagnostic value of pro-gastrin-releasing peptide for small cell lung cancer: a meta-analysis. Clin Chem Lab Med. 2011;49:1039–1046.
   PubMed Web of Science ®Google Scholar
• Yang D-W, Zhang Y, Hong Q-Y, et al. Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients. Cancer. 2015;121 Suppl 17:3113–3121.
   PubMed Web of Science ®Google Scholar
• Korse CM, Taal BG, Bonfrer JM, et al. An elevated progastrin-releasing peptide level in patients with well-differentiated neuroendocrine tumours indicates a primary tumour in the lung and predicts a shorter survival. Ann Oncol. 2011;22:2625–2630.
   PubMed Web of Science ®Google Scholar
• Tang J-H, Zhang X-L, Zhang Z-H, et al. Diagnostic value of tumor marker pro-gastrin-releasing peptide in patients with small cell lung cancer: a systematic review. Chin Med J (Engl). 2011;124:1563–1568.
   PubMed Web of Science ®Google Scholar
• Ono A, Naito T, Ito I, et al. Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer. Lung Cancer. 2012;76:439–444.
   PubMed Web of Science ®Google Scholar
• Roesler R, Schwartsmann G. Gastrin-releasing peptide receptors in the central nervous system: role in brain function and as a drug target. Front Endocrinol (Lausanne). 2012;3:159.
   PubMedGoogle Scholar
• Flores DG, Meurer L, Uberti AF, et al. Gastrin-releasing peptide receptor content in human glioma and normal brain. Brain Res Bull. 2010;82:95–98.
   PubMed Web of Science ®Google Scholar
• Abujamra AL, Almeida VR, Brunetto AL, et al. A gastrin-releasing peptide receptor antagonist stimulates Neuro2a neuroblastoma cell growth: prevention by a histone deacetylase inhibitor. Cell Biol Int. 2009;33:899–903.
   PubMed Web of Science ®Google Scholar
• Kang J, Ishola TA, Baregamian N, et al. Bombesin induces angiogenesis and neuroblastoma growth. Cancer Lett. 2007;253:273–281.
   PubMed Web of Science ®Google Scholar
• Carroll RE, Matkowskyj KA, Chakrabarti S, et al. Abberrant expression of gastrin-releasing peptide and its receptor by well-differentiated colon cancers in humans. Am J Physiol. 1999;276:G655–G665.
   Google Scholar
• Matusiak D, Glover S, Nathaniel R, et al. Neuromedin B and its receptor are mitogens in both normal and malignant epithelial cells lining the colon. Am J Physiol (Gastrointest Liver Physiol). 2005;288:G718–G728.
   Google Scholar
• Zou H, Thomas SM, Yan Z-W, et al. Human rhomboid family-1 gene RHBDF1 participates in GPCR-mediated transactivation of EGFR growth signals in head and neck squamous cancer cells. Faseb J. 2009;23:425–432.
   PubMed Web of Science ®Google Scholar
• Hohla F, Winder T, Greil R, et al. Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives. World J Gastroenterol. 2014;20:6102–6112.
   PubMed Web of Science ®Google Scholar
• Carlesso FN, Fuscaldi LL, Araujo RS, et al. Evaluation of 99mTc-HYNIC-betaAla-Bombesin(7-14) as an agent for pancreas tumor detection in mice. Braz J Med Biol Res. 2015;48:923–928.
   PubMed Web of Science ®Google Scholar
• Cheng C, Pan L, Dimitrakopoulou-Strauss A, et al. Comparison between 68Ga-bombesin (68Ga-BZH3) and the cRGD tetramer 68Ga-RGD4 studies in an experimental nude rat model with a neuroendocrine pancreatic tumor cell line. EJNMMI Res. 2011;1:34.
   PubMed Web of Science ®Google Scholar
• Shi J, Jia B, Liu Z, et al. 99mTc-labeled bombesin(7-14)NH2 with favorable properties for SPECT imaging of colon cancer. Bioconjug Chem. 2008;19:1170–1178.
   PubMed Web of Science ®Google Scholar
• Keller G, Schally AV, Nagy A, et al. Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas. Cancer. 2005;104:2266–2274.
   PubMed Web of Science ®Google Scholar
• Van Vliet EI, Teunissen JJ, Kam BL, et al. Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy. Neuroendocrinology. 2013;97:74–85.
   PubMed Web of Science ®Google Scholar